Further analysis revealed that the percentage of CD39+CD73+ MDSCs was decreased with increasing numbers of chemotherapy cycles in the stable disease (SD) and partial response (PR) groups, whereas there was a trend toward an increase in the percentage of CD39+CD73+ MDSCs in the progressive disease (PD) group, suggesting that the changes in CD39+CD73+ MDSC frequency in NSCLC patients may be sufficient for predicting chemotherapeutic response. Here, NT5E is linked to non-small cell lung carcinoma.